[go: up one dir, main page]

MX2008011978A - Tratamiento del cancer de seno negativo al triple receptor. - Google Patents

Tratamiento del cancer de seno negativo al triple receptor.

Info

Publication number
MX2008011978A
MX2008011978A MX2008011978A MX2008011978A MX2008011978A MX 2008011978 A MX2008011978 A MX 2008011978A MX 2008011978 A MX2008011978 A MX 2008011978A MX 2008011978 A MX2008011978 A MX 2008011978A MX 2008011978 A MX2008011978 A MX 2008011978A
Authority
MX
Mexico
Prior art keywords
treatment
breast cancer
receptor negative
negative breast
triple receptor
Prior art date
Application number
MX2008011978A
Other languages
English (en)
Inventor
Kay-Oliver Kliche
Axel Mescheder
Martine Piccart
Original Assignee
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag filed Critical Medigene Ag
Publication of MX2008011978A publication Critical patent/MX2008011978A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de una preparación de liposomas para la preparación de una composición farmacéutica y el uso de esa composición para el tratamiento de cáncer de seno "negativo al triple receptor.".
MX2008011978A 2006-03-22 2007-03-16 Tratamiento del cancer de seno negativo al triple receptor. MX2008011978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06005893 2006-03-22
PCT/EP2007/002352 WO2007107305A2 (en) 2006-03-22 2007-03-16 Treatment of triple receptor negative breast cancer

Publications (1)

Publication Number Publication Date
MX2008011978A true MX2008011978A (es) 2009-04-22

Family

ID=38421534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011978A MX2008011978A (es) 2006-03-22 2007-03-16 Tratamiento del cancer de seno negativo al triple receptor.

Country Status (10)

Country Link
US (4) US8168216B2 (es)
EP (2) EP2010151B8 (es)
AU (1) AU2007228984B2 (es)
BR (1) BRPI0709075A2 (es)
CA (2) CA2922029C (es)
ES (1) ES2609388T3 (es)
MX (1) MX2008011978A (es)
RU (1) RU2448697C2 (es)
WO (1) WO2007107305A2 (es)
ZA (1) ZA200808953B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
JP5700909B2 (ja) 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
BRPI0613783A2 (pt) 2005-07-18 2011-02-01 Bipar Sciences Inc tratamento de cáncer
ES2609388T3 (es) * 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Tratamiento del cáncer de mama triple negativo a receptores
EP2061479A4 (en) 2006-09-05 2010-08-04 Bipar Sciences Inc FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
KR20100102609A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
HUE030207T2 (en) 2010-03-29 2017-04-28 Abraxis Bioscience Llc Cancer Treatment Procedures
JP6242213B2 (ja) 2010-03-29 2017-12-06 アブラクシス バイオサイエンス， エルエルシー 薬物送達および治療用薬剤の有効性を向上させる方法
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
KR102122941B1 (ko) * 2012-07-13 2020-06-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
MX2015007185A (es) * 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
TWI760319B (zh) * 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
US20180207177A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)
EP3595636A4 (en) * 2017-03-16 2021-01-13 Children's Medical Center Corporation ENGINEERED LIPOSOMES USED AS THERAPEUTIC AGENTS TARGETING CANCER
TW202337497A (zh) 2022-02-18 2023-10-01 中國大陸商重慶明道浩悅生物科技有限公司 鼻內調配物及抗sars-cov-2棘蛋白抗體

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197439B (es) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
WO1993018751A1 (en) 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
EP0642586A4 (en) 1992-05-21 1995-11-29 Penn State Res Found CULTURAL -i (TAXUS) FABRIC AS A SOURCE OF TAXOL, RELATED TAXANS AND OTHER NEW ANTI-TUMOR / ANTI-VIRAL SUBSTANCES (01/20/94).
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DE4430593C2 (de) 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
WO1998022451A1 (fr) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Derives taxol
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US20030087954A1 (en) 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
DE69729128T2 (de) 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
US6214821B1 (en) * 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
KR100591767B1 (ko) 1999-09-09 2006-06-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀
AU2001253334A1 (en) 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
AU6627201A (en) 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
UY27185A1 (es) 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US20030008014A1 (en) 2001-06-20 2003-01-09 Shelness Gregory S. Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells
CN1555253A (zh) 2001-09-13 2004-12-15 ������ѧ�����о�Ժ 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
WO2004002455A1 (en) 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
PT1530465E (pt) 2002-06-26 2010-01-05 Medigene Ag Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico
US20040076582A1 (en) 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
WO2005012488A2 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Compositions for encapsulation and controlled release
US20080063699A1 (en) 2003-10-15 2008-03-13 Michael Teifel Method of Administering Cationic Liposomes Comprising an Active Drug
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US7563570B2 (en) 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
JP5700909B2 (ja) 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
ES2609388T3 (es) 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Tratamiento del cáncer de mama triple negativo a receptores
EP2073823A1 (en) * 2006-10-13 2009-07-01 Medigene AG Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer

Also Published As

Publication number Publication date
CA2922029A1 (en) 2007-09-27
US20150359778A1 (en) 2015-12-17
ZA200808953B (en) 2009-06-24
CA2922029C (en) 2017-11-28
US20090186078A1 (en) 2009-07-23
EP2010151A2 (en) 2009-01-07
RU2448697C2 (ru) 2012-04-27
US20120183604A1 (en) 2012-07-19
US9144563B2 (en) 2015-09-29
CA2646156A1 (en) 2007-09-27
US8168216B2 (en) 2012-05-01
EP3056196A1 (en) 2016-08-17
ES2609388T3 (es) 2017-04-20
WO2007107305A3 (en) 2007-11-01
BRPI0709075A2 (pt) 2011-10-11
EP2010151B1 (en) 2016-10-12
US9707204B2 (en) 2017-07-18
EP2010151B8 (en) 2017-01-11
US20170273934A1 (en) 2017-09-28
AU2007228984B2 (en) 2012-05-03
AU2007228984A1 (en) 2007-09-27
RU2008141763A (ru) 2010-04-27
CA2646156C (en) 2016-05-24
WO2007107305A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
EP1988910A4 (en) CONJUGATES OF POLYMERS CONTAINING ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE AND THEIR PREPARATION
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2010014234A (es) Compuestos pirazol 436.
IN2014MN00139A (es)
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
UA96449C2 (en) Stable laquinimod preparations
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
DK2018170T3 (da) Lægemiddel mod brystcancer
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2009007864A (es) Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
IL196606A (en) Use of Eskin for the preparation of medical preparations and medical preparations containing Eskin for the treatment of diseases

Legal Events

Date Code Title Description
FG Grant or registration